
Patients with allergic rhinitis and allergic to cedar pollinosis have lower saliva-secretory IgA than healthy subjects

Our Research Division (Research Center) conducted research and it was found that the patients with allergic rhinitis and allergic to cedar pollinosis have lower saliva-secretory IgA than healthy subjects.

Allergic rhinitis is an allergic disease with three main symptoms: sneezing, aqueous rhinorrhea and nasal obstruction, and the number of patients is steadily increasing mainly in developed countries, and it is estimated that more than 600 million people worldwide will be affected. In particular, cedar pollinosis, one of the seasonal allergic rhinitis, is a disease that affects about 40% of the Japan population, and the Cabinet Office announced in 2023 that it would take measures and it is a disease that has become a social issue.

This time, a paper summarizing a study by our Research Center comparing saliva-secretory IgA in the saliva of patients with allergic rhinitis and allergic to cedar pollinosis with healthy subjects has been published in Acta Scientific MEDICAL SCIENCES.

【Summary】

- It was found that the saliva-secretory IgA concentration in the patients with allergic rhinitis and allergic to cedar pollinosis was significantly reduced compared to the saliva-secretory IgA concentration in the saliva of healthy subjects.
- The above results suggest that the onset and/or severity of allergic rhinitis and allergic to cedar pollinosis may be suppressed if the production of saliva-secretory IgA in saliva can be enhanced in the patients with allergic rhinitis and allergic to cedar pollinosis.

【Publication】

Title: Acta Scientific MEDICAL SCIENCES Volume 7 Issue 11 November 2023

URL: <https://actascientific.com/ASMS/ASMS-07-1703.php>

【About EPS Innovative Medicine Co., Ltd.】

We are a core company of EPS Creative Health Technology Group Co., Ltd. in the pharmaceutical discovery business. Our goal is to develop the seeds introduced from academia and Biotech venture companies and the seeds found in our research department based on the knowledge and know-how cultivated by the EPS Group over many years, expanding the value of seeds and aims at promoting to Japan and China markets, or to license out to the partner enterprises.

Inquiries regarding this matter

| |
|---|
| EPS Innovative Medicine Co., Ltd. Research Center Kazuki Tajima E-mail : tajima.kazuki374@eps.co.jp |
|---|